Max Robotics — Global Service Robot Directory + US Certification

About

Torai Enomoto is a rising surgical oncologist whose research focuses on optimizing outcomes in minimally invasive urologic oncology, particularly robotic and laparoscopic approaches for renal cell carcinoma and bladder cancer. His work centers on preserving renal function during partial nephrectomy, where he has made significant contributions by investigating how surgical technique—such as single-layer versus double-layer renorrhaphy—and warm ischemic time impact postoperative kidney recovery. His 2022 study on the relationship between warm ischemic time and Trifecta achievement has garnered 6 citations, while his 2024 multicenter cohort study comparing renorrhaphy techniques has already attracted 5 citations, reflecting growing interest in his findings. Enomoto has also advanced the field of bladder cancer treatment, examining split-dose cisplatin-based neoadjuvant chemotherapy followed by robotic-assisted radical cystectomy to mitigate nephrotoxicity in muscle-invasive disease. Additionally, his narrative review on robot-assisted radical cystectomy with intracorporeal ileal neobladder highlights his expertise in complex reconstructive surgery. Through his methodical investigation of surgical refinements and perioperative outcomes, Enomoto is helping to define best practices that balance oncologic efficacy with renal preservation, making his work essential reading for surgeons seeking to improve patient quality of life after cancer treatment.